BACKGROUND: Sirolimus was originally used as an immunosuppressant drug but recent reports have indicated that it may have other potential biological effects as an anticancer drug. The chemopreventive efficacy of sirolimus was evaluated in an experimental model of invasive urinary bladder cancer. MATERIALS AND METHODS: ICR mice received N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in drinking water for a period of twelve weeks. Sirolimus was administered 5 days a week. Animals were sacrificed either one or four weeks after their final treatment. Ki-67 was immunohistochemically analysed in paraffin-embedded tissue. RESULTS: No evidence of host toxicity was found. The incidence of BBN-induced invasive urothelial carcinoma was significantly reduced in mice treated with sirolimus. Preneoplastic and neoplastic lesions exhibited a significant decrease in cellular proliferation. CONCLUSION: Histopathological and immunohistochemical studies showed that sirolimus reduced tumour incidence and proliferation. Sirolimus should be considered for further in vitro and in vivo studies in order to provide evidence of effectiveness.
BACKGROUND:Sirolimus was originally used as an immunosuppressant drug but recent reports have indicated that it may have other potential biological effects as an anticancer drug. The chemopreventive efficacy of sirolimus was evaluated in an experimental model of invasive urinary bladder cancer. MATERIALS AND METHODS: ICR mice received N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in drinking water for a period of twelve weeks. Sirolimus was administered 5 days a week. Animals were sacrificed either one or four weeks after their final treatment. Ki-67 was immunohistochemically analysed in paraffin-embedded tissue. RESULTS: No evidence of host toxicity was found. The incidence of BBN-induced invasive urothelial carcinoma was significantly reduced in mice treated with sirolimus. Preneoplastic and neoplastic lesions exhibited a significant decrease in cellular proliferation. CONCLUSION: Histopathological and immunohistochemical studies showed that sirolimus reduced tumour incidence and proliferation. Sirolimus should be considered for further in vitro and in vivo studies in order to provide evidence of effectiveness.
Authors: Igor Makhlin; Jiaru Zhang; Christopher J Long; Karthik Devarajan; Yan Zhou; Andres J Klein-Szanto; Min Huang; Jonathan Chernoff; Stephen A Boorjian Journal: BJU Int Date: 2010-11-02 Impact factor: 5.588
Authors: Andreia Henriques; Regina Arantes-Rodrigues; Ana I Faustino-Rocha; Catarina I Teixeira-Guedes; Jacinta Pinho-Oliveira; Daniela Talhada; José H Teixeira; Andreia Andrade; Bruno Colaço; Maria N Paiva-Cardoso; Maria J Pires; Ana Mvd Ferreira; Fernando M Nunes; Paula A Oliveira Journal: Iran J Basic Med Sci Date: 2014-02 Impact factor: 2.699
Authors: Céu Costa; Sofia Pereira; Luís Lima; Andreia Peixoto; Elisabete Fernandes; Diogo Neves; Manuel Neves; Cristiana Gaiteiro; Ana Tavares; Rui M Gil da Costa; Ricardo Cruz; Teresina Amaro; Paula A Oliveira; José Alexandre Ferreira; Lúcio L Santos Journal: PLoS One Date: 2015-11-16 Impact factor: 3.240